Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors

Shinya Takada¹*, Hashishita Hirokazu¹, Kayo Yamagishi¹, Sato Hideki², Endo Masayuki¹

Abstract

Medications that target programmed cell death-protein-1 (PD-1) have proven effective. However, blockade of PD-1/Programmed death-1 ligand 1 (PD-L1) causes immune-related adverse events (irAEs). Characteristics of this irAE include many symptom, low in frequency, and difficulty in prevention. The key to a successful ICI-related treatment lies in the management of irAEs resulting from immune checkpoint inhibitor (ICI) treatment. Although it is difficult to predict irAE, we tried to extract features of irAE expression from analysis of real-world database. This study used data extracted from the Japan Adverse Drug Event Report (JADER) database to assess risk factors associated with serious side effects of irAE, type 1 diabetes (T1DM). The analysis targets were nivolumab, atezolizumab, durvalumab, and pembrolizumab, and the study period was from July 2014 to June 2019. Analysis of Japanese population data confirmed that being women and having melanoma were risk factors for developing ICI-related T1DM. Analysis using this database in combination with information on ICI-related T1DM provides information and guidelines that will help in the safer treatment of ICI in the future.

Keywords: Immune checkpoint inhibitor- Japanese Adverse Drug Event Report database- type 1 diabetes

Asian Pac J Cancer Prev, 21 (6), 1697-1699

Introduction

Treatments that target programmed cell death-protein-1 (PD-1) have significantly improved the clinical outcomes in patients with various malignancies (Barroso-Sousa et al., 2018; Godwin et al., 2017). Blocking of PD-1/PD-L1 signaling using monoclonal antibodies results in reactivation of T-cell-mediated anti-tumor immunity, resulting in a continuous anti-cancer response. Adverse-effects associated with PD-1/PD-L1 blockade have been characterized by a distinct range of toxic effects, termed immune-related adverse events (irAEs). The key to the successful treatment of malignancies lies in the management of ICI treatment-associated irAEs. It is known that, although it is low, the occurrence of irAE varies. However, irAE can occasionally lead to extremely severe complications. For example, the frequency of type 1 diabetes mellitus (T1DM) is known to be less than 1%, and its incidence is rare, thus the underlying pathological mechanisms and risk factors for T1DM are unknown (Barroso-Sousa et al., 2018; Godwin et al., 2017). Although there is no clear difference between general type 1 fulminant diabetes and irAE-induced T1DM with respect to the symptoms, the risk factors and patient background associated with the onset differ; however, the details are not clear. A meta-analysis has been performed to investigate the development of ICI-induced T1DM. According to a previous report, the median T1DM after anti-PD1/PD-L1 treatment was 49 days, and 71% of the onset cases occurred within three months after the beginning of the treatment (Akturk et al., 2019). By using JADER, a voluntary reporting system in various backgrounds, and analyzing large-scale data using actual data, we believe that risk factors for adverse effects can be determined. Therefore, we examined the risk of developing T1DM in Japanese patients - being treated with ICI - using Japanese Adverse Drug Event Report (JADER) database.

Materials and Methods

Database information

Since April 2004, PMDA has reported cases of adverse events related to JADER drug therapy. This retrospective study employed JADER, an open-access database that serves as a voluntary report reporting system. The database consists of four data tables: patient demographics (demo), drug information (drugs), adverse
events (reac), and primary illnesses (history) Figure 1. It renders informed consent unnecessary as information that can be used to identify individuals - such as patient name - is anonymized. The side effect report was downloaded from PMDA website (https://www.info.pmda.go.jp/fukusayoudb/CsvDownload.jsp), and the analyzed extraction period was from July 2014 to June 2019. We targeted four different ICI (nivolumab, atezolizumab, durvalumab, pembrolizumab). We extracted and analyzed the reports on the development of type 1 diabetes by ICI and non-ICI. And, a logistic regression analysis with age, sex, and cancer type as covariates of the risk of ICI-related TIDM were performed. This study was approved by the ethics committee of Hokkaido Cancer Center, Sapporo, Japan (Approval No: 31-57).

### Statistical analysis

A chi-squared test analysis was used to compare the characteristics of patients. Multiple logistic regression analysis was used to extract risk factors for ICI-induced T1DM. Two-sided P-values less than 0.05 were considered significant. All analyses were performed using BellCurve for Excel (Social Survey Research Information Co., Ltd.).

### Results

As shown in Figure 1, after merging databases three tables using ID numbers (DRUG (3,492,552 reports), REAC (1,199,372 reports), and Medical history (942,171 reports)), a total of 595,954 patients information were obtained. We extracted and analyzed the reports on the onset of type 1 diabetes by ICI and non-ICI.

**Comparison of ICI and non-ICI type 1 diabetes incidence**

The incidence of T1DM was significantly higher in

### Table 1. Type 1 Diabetes Mellitus in Patients Receiving Immune Checkpoint Inhibitor Therapy

| ICIs        | With ICIs | Without ICIs | Odds Ratio (95%CI) |
|-------------|-----------|--------------|--------------------|
| Nivolumab   | 220/6301  | 706/580203   | 28.7 (24.6-33.4)   |
| Pembrolizumab| 79/3499   | 706/586425   | 18.8 (14.823.7)    |
| Durvalumab  | 1/329     | 706/586175   | 2.5 (0.4-14.3)     |
| Atezolizumab| 3/433     | 706/586071   | 5.8 (1.9-17.0)     |
| Total       | 303/10562 | 706/575942   | 23.4 (20.4-26.8)   |

#1; T1DM, type 1 diabetes mellitus

### Table 2. Multivariate Logistic Analysis of Patients with Type 1 Diabetes Mellitus

| Characteristic | Total number of cases | Cases of T1DM | Odds Ratio (95%CI) |
|---------------|-----------------------|---------------|--------------------|
| Sex (male=1,female=0) | 2944                  | 81            | 1.49 (1.12-1.97)   |
| Cancer Type (melanoma=1,other=0) | 1251                  | 47            | 2.01 (1.44-2.82)   |
| Age>70yrs (>70y=1,≤70=0) | 5408                  | 105           | 0.98 (0.76-1.29)   |

**Table 1.** Type 1 Diabetes Mellitus in Patients Receiving Immune Checkpoint Inhibitor Therapy

**Table 2.** Multivariate Logistic Analysis of Patients with Type 1 Diabetes Mellitus

---

Figure 1. JADER Database Consisting of Four Information Tables (DEMO, DRUG, REAC, medical history). The bold number shows the number of reports extracted between July 2004 and June 2019. Abbreviations: DEMO, patient demographic information; DRUG, drug information; REAC, adverse events.
patients with a history of ICI use, and the incidence in the ICI-free group was low (nivolumab: odds ratio 28.7 (24.6-33.4); pembrolizumab: odds ratio 18.8(14.823.7); atezolizumab: odds ratio 5.8(1.9-17.0); All ICI: odds ratio 23.4(20.4-26.8)). The use of durvalumab did not differ significantly from those of other ICIs (Table 1).

Multiple logistic regression analysis

Multivariate logistic regression analysis showed that the risk of T1DM was significantly higher in women (odds ratio, 1.49, 95% CI, 1.12-1.97, P <0.01) and melanoma (odds ratio, 2.01, 95% CI, 1.44-2.82, P <0.001) patients (Table 2).

Discussion

Risk factors for the development of irAE - using clinical trial data - have not been identified. Our study analyzed real-world data obtained for the Japanese population and found that there is a specific risk of ICI-related T1DM. Several clinical trials using ICIs apply strict inclusion criteria; however, these criteria are later relaxed once the drug is made publicly available. Therefore, we believe that more accurate risk factors can be verified by analyzing real-world data. The data from the Japanese population confirmed an increased risk of developing ICI-related T1DM in women and melanoma. Whether sex differences are a risk factor for all irAEs remains unclear controversial. A study on sex differences confirmed that anti-programmed cell death protein 1 therapy is associated with high risk of endocrine disorders and pneumonia in women (Duma et al. 2019). In addition, studies on cancer types have reported that women with metastatic melanoma and non-small cell lung cancer have a high incidence of irAEs (Wang et al., 2019). The human leukocyte antigen (HLA) genes are known to be related to T1DM. Among them, HLA-DQA1 is a particularly important gene. Depending on a person’s genetic background, homozygosity at the HLA-DQA1 locus can be reported as a potential risk factor for developing melanoma (Planelles et al., 2006). Our study has several limitations. First, this study was a retrospective study that analyzed a database of prior information. Second, although some potential risk factors such HLA type (Atkinson et al., 2014), environment, and viral infection are known to be associated with the development of T1DM, these could not be excluded in our study. Third, as the JADER database is based on self-reporting, so there is a possibility of reporting bias. Generally, mild side effects are rarely reported, and severe cases may be reported more frequently; such reporting bias is a feature of self-reporting databases. Moreover, though, information regarding age, sex, treatment history, complications and cancer type can be obtained from JADER, this information is limited. Furthermore, the JADER database consists of spontaneous reports and there is a lack of precise information for each patient, and inadequate reports may also be included, thus all confounders might not be completely excluded in our retrospective study. Therefore, a further detailed investigation is required. However, JADER simplifies risk assessment, and provides us with powerful information from real-world data. Using this method in combination with information regarding clinical practices related to ICI-related T1DM, this method can provide useful information for safe ICI treatment in the future. Therefore, a further detailed investigation is required. On the other hand, JADER considers it a useful method because it simplifies risk assessment and provides powerful information from actual data.

In conclusion, we used a large JADER database to search for data on T1DM-related drugs and patient characteristics. As a result, women, and melanoma were identified as risk factors that induced ICI-related T1DM. Analyzing this database in combination with information on ICI-related T1DM may provide information and guidelines that may help in the safer treatment of ICI in the future.

Acknowledgements

I would like to express my gratitude to all the researchers of Hokkaido Cancer Center who participated in this study. I would especially like to thank Mr. Hashishita for his detailed advice.

Conflicts of Interest

The authors declare no conflicts of interest.

References

Akturk HK, Kahramangil D, Sarwal A, et al (2019). Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med, 36, 1075–81.

Atkinson MA, Eisenbarth GS, Michels AW (2014). Type 1 diabetes. Lancet, 383, 69–82.

Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al (2018). Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens. JAMA Oncol, 4, 173–82.

Duma N, Abdel-Ghani A, Yadav S, et al (2019). Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: Are we all equal?. Oncologist, 24, 1148–55.

Godwin JL, Jaggi S, Sirisena I, et al (2017). Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer, 5, 40.

Planelles D, Nagore E, Moret A, et al (2006). HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol, 154, 261–6.

Wang S, Cowley LA, Liu XS (2019). Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules, 24, E3214.